

Factor VIII Inhibitor Point of Care Test


Domain: Diagnostic Assay/Kit

About Technology: The technology uses gold nanoparticles conjugated with Factor VIII antigen for highly specific detection of FVIII inhibitors in plasma, enhancing antigen-antibody binding for improved assay performance. Internal validation demonstrated >90% sensitivity and specificity for detecting high-titer inhibitors (>5 BU), making it a reliable tool for monitoring hemophilia A patients at risk of clinically significant inhibitor development

Intended Use: Detect FVIII inhibitors in hemophilia A patients

Advantages:

- 20-min gold nanoparticle LFIA for rapid FVIII inhibitor detection with minimal equipment.
- Low cost (~₹100) and easy to use
- Compatible with Emicizumab and faster, more accessible, and more affordable than conventional assays.



IP Status: Filed (Indian Patent application No.- 202511083527)

Development Status: Internal validation completed

Institute(s): ICMR-National Institute of Immunohaematology (NIIH)

Inventor(s): Dr. Rucha Patil, Sharda Shanbhag, Sweta Kaskar, Moni Singh